Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 26Non-Muscle Invasive Bladder Neoplasms 13Recurrence 2Neoplasms 2Prostatic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 15Paclitaxel 13Prednisone 12Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7atezolizumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5enzalutamide 5cemiplimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × BCG Vaccine × Genitourinary × Clear all
NCT07064863 2025-07-17

BCG-TIME

Queen's University

Phase 1/2 Not yet recruiting
31 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT02010203 2020-02-17

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Heat Biologics

Phase 1/2 Terminated
104 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡